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A combination of L-dopa and carbidopa was given o~ally to 
17 patients with metastatic melanoma. Maximum tolerated 
oral doses were given, up to 4 grams daily. No response was 
seen in 15 patients evaluable for response. Toxicity was con-
siderable, with seven of17 patients ( 41 %) stopping treatment 
because of unacceptable gastrointestinal toxicity or postural 
M etastatic malignant melanoma remains relatively refractory to standard cytotoxic agents . The tra-ditional single agents, DTIC and CCNU, give response rates of approximately 15%, with vis-ceral metastases having an even lower response 
rate. Sustained complete responses are rare [1]. Newer agents like 
cis-platinum [2] and hormonal manipulation [3] have also proved 
disappointing. 
In this setting, the avai labi lity of a unique metabolic pathway in 
the melanocyte makes an attractive focus for possible selective 
chemotherapy. L-dopa is centra l to the melanin synthetic pathway 
[4], and in vitro studies have suggested that L-dopa may be cytotoxic 
to melanoma cells via intrace llular accumulation of toxic melanin 
intermediates [5 -7]. Carbidopa enhances the cytotoxicity of L-
dopa in animal studies [8], but despite this, there has not been a 
satisfactory phase II study to investigate these findings. This trial 
evaluates the use of a combination ofL-dopa and carbidopa in maxi-
mum tolerated oral doses in patients with advanced malignant mela-
noma. 
MATERIALS AND METHODS 
Consenting patients attending the Sydney Melanoma Unit with 
metastatic melanoma were eligible for the study if they had measur-
able and histologically proved pigmented malignant melanoma, no 
exposure to chemotherapy in the previous six weeks, and no medi-
cal history of cardiovascular, psychiatric, or Parkinson's disease. 
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Abbreviations: 
ECOG: Eastern Cooperative Oncology Group 
PO: progressive disease 
SO: stable disease 
hypotension. Contrary to previous anecdotal reports, there 
was no evidence that L-dopa/carbidopa treatment resulted in 
accelerated progression of metastatic melanoma. Orally ad-
ministered L-dopajcarbidopa is ineffective as therapy for ad-
vanced melanoma w h en maximum tolerated doses are used.] 
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Patients of any age were eligible. All were required to have adequate 
renal function (serum creatinine of less than 200 umol/L) and per-
formance status of Eastern Cooperative Oncology Group (ECOG) 
0-3. No chemotherapy was administered during the study. Eigh-
teen patients were registered in two institutions (Royal Prince 
Alfred Hospital and Westmead Hospital) between May 1985 and 
May 1988. Levodopa 250 mg and carbidopa 25 mg were used in 
combination as Sinemet tablets (Merke, Sharp and Dome) . Doses 
were taken with meals at a starting dose of one tablet every six hours 
and esca lated on the second day by two tablets per day, to a maxi-
mum dose of two tablets every four hours, or to the maximum 
tolerated dose. Patients were evaluated for response if they received 
more than 14 d of continuous treatment of at least 1000 mg L-dopa 
and 100 mg carbidopa per day. 
Response was assessed by changes in measurable lesions according 
to World Health Organization (WHO) criteria [9]. Treatment was 
terminated on disease progression, patient refusal, or development 
of unacceptable toxicity. 
RESULTS 
Of 18 registered patients, one withdrew from the study prior to 
receiving treatment and two were not evaluable for response due to 
unacceptable postural hypotension and nausea, respectively, at 2 and 
7 days after commencing treatment (Table I). The majority of pa-
tients were fu lly ambulant and had subcutaneous, lymph node, or 
pulmonary disease (Table I). Sinemet was the initial treatment of 
metastatic disease for ten of the 18 patients (Table I). 
No responses occurred in the fifteen patients evaluable for re-
sponse (Table II). Two patients {numbers 3 and 14, Table II) had a 
minor reduction (<25%) in size of some subcutaneous nodules 
whereas another patient (number 4, Table II) had a similar reduc~ 
tion in the size of pulmonary metastases. Similar fluctuations in the 
dimensions of metastatic melanoma deposits may occur in the ab-
sence of any treatment [10). None of these three patients reached a 
partial response and all eventually progressed on treatment after 71, 
201, and 466 days, respectively. Seven patients had stable disease of 
soft tissue metastases (subcutaneous and pulmonary) for a mean of 
148 days (SE = 142) (Table II). There was no significant difference 
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Table I. Patient C haracteristics 
Patients Registered 18 Prior Chemotherapy 
Male 
Female 
Range 
Median 
Age (yrs) 
Patients Evaluable 
Fully evaluable 
Evaluable for toxicity only 
Not available 
0 
1 
2 
3 
Performance Status• 
13 
5 
26-71 
46 
15 
2 
1 
11 
6 
0 
1 
Dacarbazine 
Dacarbazine + other 
Nil 
Sites of Metastases 
Subcutaneous or 
Lymph node (SC or LN) 
Pulmonary + SC or LN 
Liver + SC or LN 
Bone + SC or LN 
Brain + SC or LN 
Bowel + SC or LN 
Retroperitoneal + SC or LN 
• ECOG (Eastern Cooperative Oncology Group} scale 
4 
4 
10 
7 
8 
2 
1 
1 
1 
1 
between stable disease (SD) and progressive disease (PD) patients for 
mean maximum daily dose (2200 mg vs 1800 mg), although the 
mean duration of treatment was significantly shorter for PD pa-
tients (1 48 d vs 25 d, p = < 0.04) . Toxicity was significant and 
resulted in termination of treatment in 44% of patients. In four 
patients, this was nausea, anorex ia, and vomiting, which persisted 
despi te administration of regular metoclopra~rude or prochlopera-
zinc. Three patients were w ithdrawn due to postural hypoten-
sion (Table II) . Treatment was terminated in one patient due to 
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poor compliance and in nine patients due to disease progression 
(Table II) . 
DISCUSSION 
This study demonstrates that a combination of L-dopa and carbi-
dopa given in maximum tolerated oral doses was ineffective in 15 
patients with metastatic malignant melanoma, allowing exclusion 
of a 20% efficacy rate for this treatment w ith 95% probability of 
detection [11]. The majority of patients experienced significant tox-
icity . 
L-dopa is toxic in millimolar concentrations to murine melanoma 
cells in vitro [8]. Cytotoxicity may be due to inhibition of ribonu-
cleotide reductase and DNA polymerase by accumulated quinol and 
quinone intermediates of the melanin synthetic pathway [5 -7]. 
The feedback of dihydroxyindole on tyrosinase may normally pro-
tect cell s from cytotoxicity by reducing the conversion of tyrosine 
to L-dopa. In laboratory animals, L-dopa use was restricted by car-
diovascular complications, but these can be prevented by dopa decar-
boxylase inhibitors such as carbidopa. Dopa decarboxylase inhibi-
tors have been shown to increase the incorporation of dopa into 
melanoma in vivo [12]. and to enhance the cytotoxicity of dopa to 
B16 and C loudman melanoma in vivo [8] . 
C learly , the major limitation to the therapeutic use of L-dopa is 
the inability to achieve plasma concentrations approaching those 
that are cytotoxic. In the presence of dopa decarboxylase inhibitors, 
mice require L-dopa doses on the order of 100 mg/kg for anti-
melanoma effects to be noted [8], and normal maintenance doses in 
humans with Parkinson 's disease (10-15 mg/kg) only attain mean 
peak plasma L-dopa concentrations of 1-3 pg/ml [13). As evident 
in this study , gastrointestinal and cardiovascular toxicity prevents 
the escalation of oral L-dopa/carbidopa dosage beyond a mean of 
1860 mg/d, which is highly unlikely to resu lt in cytotoxic plasma 
concentrations. 
In the only previously reported ·use of L-dopa in humans with 
Table II. Details of Treated Patients 
Maximum Length of Reason for 
Dai ly Treatment Best Maximum Treatment 
Patient Dose (mg) (days) Site' Responseb Toxicity' T ermination 
1 1000 147 LN, lung SD Grade 2 N PD 
2 1500 34 LN, liver PD Grade 2 N PD 
3 1500 71 SC, LN SD Grade 2 A PO 
4 1500 466 Lung SD Grade 1 N PD 
5 1000 26 LN PO Grade 1 N Toxicity 
abdominal pain 
6 1000 2 Lung NE Postural Toxicity 
dizziness 
7 2250 27 sc PD Grade 3 N Toxicity 
8 3000 14 LN, Lung PO Grade 2 N PD 
9 1000 7 Lung, pleura NE Grade 3 N Toxicity 
10 1500 42 SC, lung PD Grade 1 N PD 
11 1000 23 sc PD Grade 3 N Toxicity 
12 Not treated 
13 2500 14 SC, LN SD Postural 
dizziness 
Toxicity 
14 1000 201 LN, lung SD Grade 2 N PD 
palpitations 
15 1000 14 SC, liver PD Grade 3 N Toxicity 
16 4000 97 sc SD Grade 2 A PO 
17 3000 21 SC, LN PD Postural T oxicity 
dizziness 
18 4000 46 LN, lun g SD Nil PD 
'LN, lymph node; SC, subcutaneous mctastatis. 
b NE, not evaluable; SD, Stable disease; PD, Progress ive disease. 
c A, Anorexia ; N , Nausea. 
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melanoma, four patients were given up to 16 g/ d of L-dopa, in the 
absence of carbidopa, givihg mean plasma levels of only 5 ,u.mol/1 
(14]. Cardiovascular toxicity was limiting, but no neurologic or 
irreversible toxicity ensued. No tumor responses occurred. Dopa-
mine (5-d infusion at 25 ,u.gjkg/min) gave plasma concentration of 
SO ,u.mol/1 and was associated with reduced thymidine uptake in 
tumor tissue in all four patients and partial resolution of hepatic 
metastases in one patient [14 ,15] . 
A previous history of melanoma is listed as a contraindication to 
the use of L-dopa in patients with Parkinson's disease [16] . This 
warning appears to be based on four case reports [ 16, 17], yet review 
of these reveals that the evidence implicating L-dopa in the exacer-
bation of melanoma was in each case anecdotal. The apparent "exac-
erbation" of melanoma in two patients who commenced anti-Par-
kinsonian treatment was quite in keeping with the natural pattern of 
the disease and is likely to be coincidental. In a third case, the patient 
clearly had an untreated primary malignant melanoma prior to a 
brief three-week course of L-dopa, and died of metastatic disease. In 
the fourth case, a patient with history of excised malignant mela-
noma three years previously died of cerebral metastases two months 
after commencing dopa, and the histology of the brain metastases 
were not confirmed. 
No patients in this study had an apparent increase in tumor 
growth rate after . commencement of L-dopa/ carb~dopa. Thus, 
while L-dopajcarbtdopa may be regarded as meffecttve treatment 
for metastatic melanoma, a previous history of melanoma should 
not be regarded as a contraindication to anti-Parkinsonian therapy 
with these agents . 
We would like to thank He/we Edouard for preparation of the matwscript. 
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